Solid Biosciences

Historical price data

Solid Biosciences is a publicly traded biotech focused on advancing a portfolio of gene therapy candidates for rare neuromuscular and cardiac diseases, including lead program SGT-003 for Duchenne muscular dystrophy. The company's strategy is dual-pronged: progressing specific therapeutic candidates through clinical development while investing in proprietary platform technologies, such as libraries of genetic regulators, to enhance gene therapy delivery and efficacy broadly. With a founding story rooted in personal patient experience, Solid aims to improve daily life outcomes by uniting expertise in science, technology, and disease management.

Developing innovative libraries of genetic regulators (e.g., promoters, enhancers, microRNA targets) designed to control transgene expression, improve safety, enhance tissue-specificity, and optimize biodistribution for gene therapies.

Faces intense competition in Duchenne from Sarepta and Pfizer, but is a pioneer in its cardiac gene therapy programs. Differentiation hinges on demonstrating superior safety/efficacy via its proprietary platform technologies.